The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I clinical study of cabazitaxel plus prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in a Japanese population.
Shunji Takahashi
Research Funding - Sanofi
Hirofumi Mukai
No relevant relationships to disclose
Hirotsugu Uemura
Research Funding - Sanofi
Hiroji Uemura
No relevant relationships to disclose
Takeo Kosaka
No relevant relationships to disclose
Hiroyuki Nishiyama
No relevant relationships to disclose
Kazuhiro Suzuki
Consultant or Advisory Role - Janssen; Millennium; Takeda
Honoraria - Astellas Pharma; Sanofi ; Takeda
Research Funding - Astellas Pharma; Sanofi ; Takeda
Yoshiyuki Kakehi
No relevant relationships to disclose
Koji Okihara
No relevant relationships to disclose
Shunichi Namiki
No relevant relationships to disclose
Osamu Ogawa
No relevant relationships to disclose
Masashi Kato
No relevant relationships to disclose
Yasutomo Nakai
No relevant relationships to disclose
Keiji Ohno
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi